Core Viewpoint - 康沣生物-B (06922) reported significant revenue growth and a reduction in losses for the first half of 2025, driven by increased sales of respiratory intervention products following regulatory approvals [1] Financial Performance - Revenue reached 51.106 million yuan, representing a year-on-year increase of approximately 162% [1] - Gross profit amounted to 34.312 million yuan, reflecting a year-on-year growth of about 125% [1] - Loss attributable to shareholders narrowed to 23.817 million yuan, a reduction of 54.35% compared to the previous year [1] - Earnings per share reported a loss of 0.1 yuan [1] Product and Market Development - Revenue growth was primarily driven by the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products by 波科国际医疗贸易 (Shanghai) Co., Ltd. also increased during the reporting period [1] Strategic Initiatives - The reduction in losses is attributed to the company's optimized development strategy and effective measures implemented for group cost control [1]

Core Viewpoint - 康沣生物-B (06922) reported a significant increase in revenue and a reduction in losses for the first half of 2025, driven by the sales of newly approved respiratory intervention products [1] Financial Performance - Revenue reached 51.106 million yuan, representing a year-on-year increase of approximately 162% [1] - Gross profit amounted to 34.312 million yuan, reflecting a year-on-year growth of about 125% [1] - Loss attributable to the parent company narrowed to 23.817 million yuan, a reduction of 54.35% compared to the previous year [1] - Earnings per share reported a loss of 0.1 yuan [1] Product and Market Development - Revenue growth was primarily driven by the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products distributed by 波科国际医疗贸易 (Shanghai) Co., Ltd. also increased during the reporting period [1] Strategic Initiatives - The reduction in losses is attributed to the company's optimized development strategy and effective measures implemented for group cost control [1]

Core Viewpoint - 康沣生物-B (06922.HK) reported significant revenue growth and reduced losses for the six months ending June 30, 2025, driven by increased sales of respiratory intervention products following regulatory approval [1] Financial Performance - Revenue increased to RMB 51.1 million, representing a year-on-year growth of 162.4% [1] - Losses decreased from RMB 56.0 million for the six months ending June 30, 2024, to RMB 27.2 million for the same period in 2025, a reduction of RMB 28.8 million or 51.4% [1] Product Development - The revenue growth was primarily attributed to the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products distributed by 波科国际医疗贸易 (Shanghai) Co., Ltd. also contributed to the revenue increase during the reporting period [1]

康灃生物科技（上海）股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 本公司欣然宣布，於2025年3月6日，本集團的惡性狹窄冷凍消融系統（「惡性狹窄 冷凍消融系統」），本集團的呼吸介入產品之一，由冷凍治療設備及氣道冷凍消融 導管組成，已獲得國家藥品監督管理局（「國家藥監局」）授出的批文。 惡性狹窄冷凍消融系統為用於消融惡性氣道腫瘤組織、減少氣道再狹窄頻次的自 主研發冷凍消融系統。在手術過程中，惡性狹窄冷凍消融系統利用冷凍消融系統 產生的超低溫消融氣管腔內及腔壁的腫瘤細胞，然後通過復溫進一步破壞腫瘤細 胞。冷凍消融球囊能在較大範圍內對惡性腫瘤進行更徹底的消融，並推遲再狹窄 的時間。 本公司無法保證惡性狹窄冷凍消融系統的未來前景。本公司股東及潛在投資者於 買賣本公司證券時務請審慎行事。 承董事會命 康灃生物科技（上海）股份有限公司 董事會主席 李克儉先生 香港，202 ...